Satralizumab for Thyroid Eye Disease

(SatraGO-1 Trial)

Not currently recruiting at 81 trial locations

Overseen By Reference Study ID Number GP44467 www.roche.com/about_roche/roche_worldwide.htm

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Hoffmann-La Roche

Disqualifiers: Pregnancy, Breastfeeding, Ophthalmic disease, others

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 5 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 12

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the effectiveness and safety of satralizumab for people with thyroid eye disease, a condition that can cause eye swelling and discomfort. Satralizumab is a medicine designed to block signals in the body that lead to inflammation. Participants will receive either this treatment or a placebo, a harmless substance used for comparison. Those diagnosed with thyroid eye disease and experiencing ongoing symptoms might be suitable for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to the potential availability of a new treatment.

Do I have to stop taking my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications. Please consult with the study team for guidance.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Is there any evidence suggesting that satralizumab is likely to be safe for humans?

Research has shown that satralizumab has been tested for safety in treating other conditions and is generally well-tolerated. In earlier studies, patients experienced mild side effects like headaches or reactions at the injection site. These side effects were not serious and usually resolved on their own. Importantly, satralizumab is already approved for other diseases, indicating its safety.

When tested, the most common side effects of satralizumab were not serious, meaning most people did not encounter major issues while using it. However, like any medication, there is always a small chance of side effects. Prospective trial participants should discuss any concerns with their doctor. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for thyroid eye disease?

Satralizumab is unique for treating Thyroid Eye Disease because it targets the IL-6 receptor, a different approach from the standard treatments that typically focus on reducing inflammation with corticosteroids or using immunosuppressive therapies. This distinct mechanism of action may offer a more targeted way to manage the underlying immune response driving the disease. Researchers are excited about satralizumab because it could potentially provide a more precise and effective treatment option, reducing side effects associated with broader immunosuppression.

What evidence suggests that satralizumab might be an effective treatment for thyroid eye disease?

Research shows that satralizumab, which participants in this trial may receive, might help treat thyroid eye disease (TED) by blocking a specific protein involved in inflammation. Studies have found that targeting this protein can reduce symptoms like eye bulging and discomfort in TED. People using satralizumab for other conditions have experienced less inflammation and improved symptoms. Early trials in TED suggested that satralizumab could lower eye swelling and enhance quality of life. While more research is needed, these findings offer hope that satralizumab could be a promising treatment for TED. ^{1 2 6 7 8}

Who Is on the Research Team?

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Are You a Good Fit for This Trial?

This trial is for individuals with thyroid eye disease (TED) who have a stable condition without significant changes in symptoms or measurements recently. It's not for those needing urgent eye surgery, planning surgery during the study, pregnant or breastfeeding women, or anyone with other serious eye diseases that could affect results.

Inclusion Criteria

I have been diagnosed with thyroid eye disease.

Exclusion Criteria

Identified pre-existing ophthalmic disease that, in the judgment of the investigator, would preclude study participation or complicate interpretation of study results, including corneal decompensation unresponsive to medical management and including ophthalmic diseases that will likely require prohibited therapy during the study

My eye condition improved before the study started.

I don't need eye surgery or treatment during the study.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Part I

Participants receive satralizumab or placebo every 4 weeks

24 weeks

6 visits (in-person)

Treatment Part II

Proptosis response-based individualized treatment

24 weeks

6 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Satralizumab

Trial Overview The trial is testing Satralizumab, an antibody targeting IL-6 receptors to treat TED. Participants will receive it subcutaneously and be compared to others receiving a placebo to measure effectiveness and safety.

How Is the Trial Designed?

Group I: Satralizumab Experimental Treatment 1 Intervention

In the Part I period, participants will receive satralizumab every 4 weeks (q4w) followed by proptosis response-based individualized treatment in Part II of the study

Group II: Placebo Placebo Group 1 Intervention

In the part I period, participants will receive placebo q4w followed by proptosis response-based individualized treatment in part II of the study

Satralizumab is already approved in United States, European Union, Canada, Japan, Switzerland for the following indications:

Approved in United States as Enspryng for:

• Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive

Approved in European Union as Enspryng for:

• Neuromyelitis optica spectrum disorder (NMOSD)

Approved in Canada as Enspryng for:

• Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive

Approved in Japan as Enspryng for:

• Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive

Approved in Switzerland as Enspryng for:

• Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive

Who Is Running the Clinical Trial?

Hoffmann-La Roche

Lead Sponsor

Trials

2,482

Recruited

1,107,000+

Headquarters

Basel, Switzerland

Known For

Precision medicine

Top Products

Avastin, Herceptin, Rituxan, Accu-Chek

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Published Research Related to This Trial

Teprotumumab significantly reduces proptosis (eye bulging) and inflammation in patients with chronic Thyroid Eye Disease (TED), with an average reduction of 3.5 mm in proptosis after treatment.

In a study of 31 patients who received an average of 7 infusions, 67% of those with diplopia (double vision) experienced a significant improvement, and there was a notable reduction in both muscle and fat tissue volume in the orbits.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Teprotumumab for the treatment of chronic thyroid eye disease. Ugradar, S., Kang, J., Kossler, AL., et al.[2022]

In a study of 18 patients with thyroid eye disease who did not respond to multiple steroid treatments, Tocilizumab significantly improved disease activity, as shown by a mean reduction of 5.89 points in the Clinical Activity Score (CAS).

Tocilizumab also led to a substantial decrease in thyroid-stimulating immunoglobulin (TSI) levels by 76.18% and improved symptoms such as proptosis and extraocular motility, with no severe side effects reported.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of active corticosteroid-resistant graves' orbitopathy. Pérez-Moreiras, JV., Alvarez-López, A., Gómez, EC.[2022]

Teprotumumab, an IGF-1R inhibitor approved for thyroid eye disease (TED), has shown effectiveness in improving symptoms like proptosis and diplopia even in patients with long-standing disease or those who have not responded to previous treatments.

Recent reports suggest that teprotumumab can benefit patients regardless of disease duration or inflammation markers, indicating its potential as a versatile treatment option for TED.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. Subramanian, PS., Cho, RI., Kahana, A.[2023]

In a study of 162 multiple sclerosis patients treated with alemtuzumab, 44% developed thyroid dysfunction, primarily Graves' disease, with 16% referred for thyroid eye disease (TED) evaluation.

Some patients experienced severe TED requiring systemic immunosuppression, highlighting the need for regular monitoring and early referral to ophthalmology, especially for those with elevated TSH-receptor antibody levels.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series. Roos, JCP., Moran, C., Chatterjee, VK., et al.[2022]

In a study of nine patients with chronic thyroid eye disease (TED) and low clinical activity scores, treatment with teprotumumab resulted in a significant average reduction of 4.0 mm in proptosis (eye bulging) immediately after treatment, indicating its efficacy.

Despite some reported side effects, such as myalgias and hair thinning, teprotumumab appears to be a promising treatment option for patients with chronic TED, as evidenced by sustained proptosis reduction observed in follow-up assessments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Teprotumumab for chronic thyroid eye disease. Ozzello, DJ., Dallalzadeh, LO., Liu, CY.[2022]

In a study involving 51 patients with thyroid eye disease (TED), teprotumumab was found to be highly effective, with 89.2% of previously placebo-treated patients responding positively after receiving the treatment, showing a significant reduction in proptosis (eye bulging).

No new safety concerns were identified during the study, although mild hearing impairment was reported in some cases; this suggests that teprotumumab is a safe option for patients with TED, even those with longer disease durations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Douglas, RS., Kahaly, GJ., Ugradar, S., et al.[2022]

In a study of 131 patients with thyroid eye disease treated with teprotumumab, 77% experienced significant improvement in proptosis, indicating the drug's efficacy in reducing eye bulging associated with the condition.

While 81.7% of patients reported adverse events, most were mild and reversible; however, serious adverse events occurred in some cases, leading to treatment discontinuation in 12.2% of patients, highlighting the need for careful monitoring and patient education regarding potential risks.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multi-Center Study. Shah, SA., Amarikwa, L., Sears, CM., et al.[2023]

Alemtuzumab-induced thyroid eye disease (AI-TED) can present with greater severity compared to conventional thyroid eye disease (TED), as indicated by an average clinical activity score of 3.3 among 16 patients studied, with some experiencing scores as high as 5.0 during active phases.

AI-TED may develop several months after the onset of Graves' disease, highlighting the need for healthcare providers to monitor patients for potential severe TED following treatment with alemtuzumab.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Alemtuzumab-Induced Thyroid Eye Disease: A Comprehensive Case Series and Review of the Literature. Nirmalan, A., Blecher, N., Hyder, S., et al.[2023]

In a study of 27 patients treated with teprotumumab for thyroid eye disease, 81.5% developed new otologic symptoms, with tinnitus and ear fullness being the most common, but only 45.5% of those with hearing loss experienced symptom resolution after treatment.

Teprotumumab was associated with sensorineural hearing loss in 5 out of 6 patients tested, and a prior history of hearing loss was identified as a significant risk factor, highlighting the need for careful monitoring and screening for hearing issues in patients undergoing this treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease. Sears, CM., Azad, AD., Amarikwa, L., et al.[2023]

In a study of 22 patients receiving teprotumumab for thyroid eye disease, 38.6% of ears showed hearing loss that met criteria for ototoxicity, particularly affecting high and middle frequencies.

Older patients were more likely to experience hearing loss after treatment, highlighting the need for regular audiometric testing to monitor hearing function during teprotumumab therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab. Keen, JA., Correa, T., Pham, C., et al.[2023]

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/NCT05987423

NCT05987423 | A Study to Evaluate the Efficacy, Safety, ... A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease (SatraGO-1).

2. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/41066062/

Targeting IL-6 Receptor Signaling with Satralizumab in ... Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials · Abstract.

3. genentech-clinicaltrials.com genentech-clinicaltrials.com/content/patient-platform/na/us/en/trials/eye-disorder/thyroid-eye-disease/a-study-to-evaluate-the-efficacy--safety--pharmacokinet-16079.pdf

A clinical trial to compare satralizumab against placebo in ... This clinical trial aims to compare the effects, good or bad, of satralizumab versus placebo in people living with thyroid eye disease (TED, also known as ...

4. clinicaltrials.gov clinicaltrials.gov/study/NCT02028884

NCT02028884 | Efficacy and Safety Study of Satralizumab ... The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with ...

5. medically.roche.com medically.roche.com/global/en/ophthalmology/asoprs-2025/thyroid-eye-disease.html

Thyroid Eye Disease - ASOPRS 2025 Primary Results of the Phase 3 SatraGO-1 and Satra-GO-2 Trials: Efficacy and Safety of Satralizumab▽ in Thyroid Eye Disease. Speakers.

6. genentech-clinicaltrials.com genentech-clinicaltrials.com/en/trials/eye-disorder/thyroid-eye-disease/a-study-to-evaluate-the-efficacy--safety--pharmacokinet-83677.html

Clinical trial for Eye Disorder, Thyroid eye disease (TED... This clinical trial aims to compare the effects, good or bad, of satralizumab versus placebo in people living with thyroid eye disease (TED)

7. medically.gene.com medically.gene.com/global/en/unrestricted/ophthalmology/ASOPRS-2025/asoprs-2025-presentation-briceno-primary-results-of-the.html

Primary Results of the Phase 3 SatraGO-1 and Satra-GO-2 Trials Primary Results of the Phase 3 SatraGO-1 and SatraGO-2 Trials: Efficacy and Safety of Satralizumab in Thyroid Eye DiseaseCésar A. Briceño, ...

8. io.nihr.ac.uk io.nihr.ac.uk/wp-content/uploads/2025/08/37732-Satralizumab-for-Thyroid-Eye-Disease-V1.0-AUG2025-NON-CONF.pdf

Health Technology Briefing August 2025 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and. Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease ( ...